Gilead Sciences, Inc. operates as a biopharmaceutical company.
The company is committed to advancing innovative medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis, coronavirus disease 2019 (COVID-19), cancer, an…
Analysis
Quality compounder
Gilead Sciences, Inc. earns the quality_compounder label: good underlying economics priced fairly, with no obvious bargain or excess. Worth noting: the cash the business generates has lagged behind what the income statement shows.
On valuation, the picture is attractive. The owner-earnings multiple stands at 13.7×; owner earnings: the cash an owner could take out each year. The implied growth embedded in that price is around 1% a year, against analyst forecasts of 12%. The price, in other words, assumes less than the experts do.
Growth is tepid; the safety picture is adequate. The company scores 16/20 on our value-creation score: strong value creator. Analyst sentiment is cautious.
Flags to be aware of: Reported profits have run ahead of actual cash for several periods. As always: this describes the company's numbers; it is not a recommendation.
360° rank · history
1007550250
Jan 202596
73
20252026
All-time high
96
Jan 2025
All-time low
73
Jun 2026
Average rank
86
across all years
Detailed & Historical Ranks
Deep dive into 15 detailed ranks and 3 years of history.
Current202520242023
Price/Sales
71
28
—
—
Price/Earnings
1
57
—
—
Price/Book
23
16
—
—
Dividend Yield
100
98
—
—
Value (overall)
67
67
—
—
Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.